C4x Discry Hdgs Share News (C4XD)

AIM WINNERS & LOSERS: C4X shares jump on agreement with AstraZeneca

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

C4X Discovery shares up as signs USD400 million deal with AstraZeneca

(Alliance News) - C4X Discovery Holdings PLC on Monday said it signed an exclusive worldwide licensing agreement with AstraZeneca PLC for its NRF2 Activator programme.

TRADING UPDATES: XPS Pensions revenue up; IG Design performing ahead

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

C4X raises £5.7m to support development activities

(Sharecast News) - Drug discovery company C4X announced a proposed placing to raise up to £5.7m on Thursday, to support its corporate development and ongoing commercial activities.

UPDATE: C4X Discovery raises GBP5.7 million in oversubscribed placing

C4X Discovery Holdings PLC - Manchester-based developer of drug discoveries - Raises total of GBP5.7 million from placing 22.8 million shares with institutional investors at 25 pence each. Notes placing shares represents about 9.9% of existing shares.

AIM WINNERS & LOSERS: MJ Hudson falls short of fundraising target

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

IN BRIEF: C4X plans GBP5.7 million placing to aid drug development

C4X Discovery Holdings PLC - Manchester-based developer of drug discoveries - Proposes placing to raise up to GBP5.7 million through issue of EIS/VCT shares and general placing shares at 25 pence each.

IN BRIEF: C4X Discovery sees momentum across drug discovery portfolio

C4X Discovery Holdings PLC - Manchester-based developer of drug discoveries - Says it has made continued progression across its drug discovery portfolio. Says it is in advanced stage commercial discussions for its NRF2 activator programme for inflammatory diseases with a deal anticipated in the second half of 2022. Also says its MALT-1 inhibitor programme for haematological and solid tumours has compounds, that match the leading clinical candidate in terms of in vitro and in vivo profile, is now moving towards identifying a "best-in-class shortlist of compounds".

IN BRIEF: C4X Discovery receives milestone payment from Sanofi deal

C4X Discovery Holdings PLC - Manchester-based developer of drug discoveries - Receives milestone payment of EUR3 million from French pharma firm Sanofi SA under the IL-17A inhibitor programme licence agreement, first signed in April 2021.

TRADING UPDATES: Impellam's first quarter beats pre-virus levels

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

CORRECT: UK shareholder meetings calendar - next 7 days

CORRECT: UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

C4X Discovery appoints Cathy Tralau-Stewart as new science chief

(Sharecast News) - Drug discovery company C4X announced the appointment of Catherine Tralau-Stewart as its new chief scientific officer on Tuesday, effective from 4 January.

TRADING UPDATES: Tristel, K3 Capital, MyHealthChecked expect growth

TRADING UPDATES: Tristel, K3 Capital, MyHealthChecked expect growth